Sentence examples for dose on reducing from inspiring English sources

We designed an RCT to assess the effect of FA peri-conceptional supplementation of 4 mg/day compared to the 0.4 mg/day standard dose on reducing the occurrence of major adverse pregnancy outcomes.

The primary objectives are:  to promote the implementation of pre-conceptional counselling in a formal and structured way and with defined procedures, to support a wider prevention of CMs and maternal-infant health;  to assess the effect of peri-conceptional FA supplementation of 4 mg/day compared to the 0.4 mg/day standard dose on reducing the occurrence of CMs.

Although RECORD-1 did not have a separate arm in which all patients were administered a 5-mg dose of everolimus, the model was able to detect a difference in the effect of a 5-mg and a 10-mg dose on reducing the size of target lesions by taking into account the dosing histories of individual patients.

The effects of the ultra low dose cigarette on reducing negative symptoms may be due to a pharmacological effect of the small amount of nicotine increase produced by this denicotinized cigarette.

Our other finding was that the beneficial effect of high-dose corticosteroids on reducing disease activity and improving physical health was also confined to ACPA-positive RA.

Studies have also demonstrated the prophylactic effect of low-dose aspirin on reducing the risk of future cardiovascular events in a variety of clinical settings [ 7].

Our positive results support a larger clinical trial in order to confirm the positive effect of low-dose hydrocortisone on reducing vasopressor administration after severe burn and to assess the potential beneficial effects of weaning vasopressors earlier in these patients.

CL316243 at 1 mg/kg was the most effective β3-adrenoceptor agonist and had the most potent dose-response effect on reducing cumulative food intake over time (P<0.001 after 24 hours), and this drug and dose were selected for the repeated-treatment experiment.

A phase II clinical trial showed that ocrelizumab had a dose-dependent effect on reducing the number of gadolinium-enhancing T1 lesions over 24 weeks compared with placebo in patients with RRMS [ 167].

Also, icaritin has been reported to exert a dose-dependent effect on reducing the incidence of osteonecrosis with inhibition of intravascular thrombosis and extravascular lipid deposition (Zhang et al. 2009).

Phase II clinical trials showed that daclizumab, as add-on or monotherapy in RRMS, had a dose-dependent effect on reducing relapse rate, disability progression, and the number and volume of gadolinium-enhancing T1 and T2 lesions over 12 months [ 163, 164].